Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The wholesale business for prescription pharmaceuticals and other products reported higher revenue due to increased sales of certain type 2 diabetes treatments, specialty pharmaceuticals and other products, but lower profit due to the drug price revision, efforts to improve distribution practices, and higher logistics and personnel costs. The self-medication wholesale business was affected by higher logistics costs and other expenses. The pharmaceuticals and other products manufacturing business was affected by the drug price revision, lower sales from active pharmaceutical ingredient manufacturing, depreciation expenses, and promotional expenses. The dispensing pharmacies and other businesses were affected by the drug price revision, procurement costs, and personnel costs.
No applicable items
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥1,582,760 million (YoY +3.5%) |
| Operating profit | ¥13,029 million (YoY -19.6%) |
| Ordinary income | ¥14,380 million (YoY -17.8%) |
| Profit attributable to owners of the parent | ¥8,240 million (YoY -28.5%) |
| Net income per share | ¥46.53 |
| Equity ratio | End of the current fiscal period 32.2 / End of previous period 33.7 |
| Total assets | ¥1,536,401 million |
| Net assets | ¥494,734 million |
| Cash flows from operating activities | ¥36,514 million |
| Cash flows from investing activities | ¥-10,694 million |
| Cash flows from financing activities | ¥-22,118 million |
| Cash and cash equivalents at end of period | ¥195,712 million |
| Full-year earnings forecast | Net Sales ¥3,144,000 million (YoY +1.3%) / Operating profit ¥33,900 million (YoY -6.3%) / Ordinary income ¥36,600 million (YoY -5.3%) / Profit attributable to owners of the parent ¥20,800 million (YoY -50.2%) |
| Annual Dividend Forecast | ¥68 → ¥71（+4.4%） |
| Segment revenue | Wholesale of prescription pharmaceuticals and related products ¥1,425,124 million (YoY +4.2%), Self-medication product wholesaling ¥130,582 million (YoY -3.7%), Pharmaceutical and related product manufacturing ¥23,896 million (YoY -6.6%), Dispensing pharmacies and related businesses ¥18,941 million (YoY +3.6%), Other (outside reportable segments) ¥1,228 million |
| Segment profit | Wholesale of prescription pharmaceuticals and related products ¥13,986 million (YoY -5.2%), Self-medication product wholesaling ¥1,025 million (YoY -41.6%), Pharmaceutical and related product manufacturing ¥-1,227 million, Dispensing pharmacies and related businesses ¥2 million (YoY -98.5%), Other (outside reportable segments) ¥-727 million |
| Depreciation and amortization | ¥8,251 million |
| Impairment loss | ¥147 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥37 million, Gain on sale of investment securities ¥181 million / Extraordinary loss Loss on sale of noncurrent assets ¥25 million, Loss on disposal of fixed assets ¥169 million, Impairment Losses ¥147 million, Impairment Losses on Investment Securities ¥8 million, Loss on extinguishment of shares in a merger ¥151 million |
| Disclosure regarding the going concern assumption | No applicable items |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name ArkMS株式会社 / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 191,300,000 |
| Treasury Shares at Period-End | 15,883,984 |
| Factors Behind Changes in Business Performance | The wholesale business for prescription pharmaceuticals and other products reported higher revenue due to increased sales of certain type 2 diabetes treatments, specialty pharmaceuticals and other products, but lower profit due to the drug price revision, efforts to improve distribution practices, and higher logistics and personnel costs. The self-medication wholesale business was affected by higher logistics costs and other expenses. The pharmaceuticals and other products manufacturing business was affected by the drug price revision, lower sales from active pharmaceutical ingredient manufacturing, depreciation expenses, and promotional expenses. The dispensing pharmacies and other businesses were affected by the drug price revision, procurement costs, and personnel costs. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The wholesale business for prescription pharmaceuticals and other products reported higher revenue due to increased sales volume, but lower profit owing to the negative impact of the NHI drug price revision, efforts to improve distribution practices, and higher logistics and personnel costs. Profit in the other businesses was also affected by higher logistics costs and other expenses, the drug price revision, lower sales from active pharmaceutical ingredient manufacturing, depreciation expenses for the newly constructed manufacturing building, and promotional expenses for new drugs.